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Abstract 
Purpose: To investigate the anti-hyperprolactinemic effect of Ficus pumila Linn. extract (FPLE) in rats. 
Methods: Hyperprolactinemic rats were generated by subcutaneous injection of metoclopramide 
dihydrochloride (50 mg/kg). A high dose (800 mg/kg), moderate dose (400 mg/kg), or low dose (200 
mg/kg) of FPLE was administered into the stomach of hyperprolactinemic rats for 30 days, after which 
serum sex hormones and pituitary prolactin-positive cell number and mRNA expression were measured. 
Results: FPLE had a significant effect on measures of hyperprolactinemia. Compared with 
hyperprolactinemic rats without FPLE treatment, hyperprolactinemic rats that received a high dose of 
FPLE showed altered serum estradiol, progesterone, prolactin, follicle-stimulating hormone, and 
luteinizing hormone levels (p < 0.05), as well as decreased pituitary prolactin-positive cell number (p < 
0.05) and mRNA expression (p < 0.05). 
Conclusion: FPLE can potentially be used as an anti-hyperprolactinemia treatment but further studies 
are required to ascertain its suitability. 
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Hyperprolactinemia, defined as a prolactin (PRL) 
level greater than 25 ng/ml, is one of the most 
common endocrine disorders of the 
hypothalamus-pituitary axis in young women. It is 
associated with galactorrhea and ovulatory 
dysfunction, resulting in menstrual irregularities 
and bareness [1]. Hyperprolactinemia can occur 
at any age, and its prevalence varies from 0.4 % 
in the normal adult population to 9 - 17 % in 
women with menstrual problems such as 
amenorrhea or polycysticovarian syndrome [2,3]. 
Causes of hyperprolactinemia include 
hypothalamus-pituitary lesions, pituitary tumors, 
severe liver or kidney disease, neuritis or 
irritations of the spinal cord, depression, or other 
physiological factors such as pregnancy and 
lactation [4,5]. The pharmacological agents 
currently used to treat hyperprolactinemia cause 
many side effects, such as menstrual disorder, 
and are associated with high relapse rates. 
Although bromocriptine and cabergoline are 
effective in treating hyperprolactinemia, they are 
very expensive [7], and 12 % patients cannot 
tolerate bromocriptine [6]. 
 
Since the Song Dynasty, Ficus pumila Linn. has 
been used to effectively treat Chinese women 
with galactorrhea without toxic side effects [8-9]. 
Therefore, we evaluated the anti-hyper-
prolactinemic effect of Ficus pumila Linn. extract 
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(FPLE) on serum sex hormone levels and 
pituitary prolactin (PRL)-positive cell number and 






Herbal samples of Ficus pumila Linn. were 
collected from Bozhou City, Anhui Province, 
China in July, 2014. Taxonomic identification of 
the plant was performed by Professor YanSu of 
Suizhou Central Hospital in China. A specimen of 
the herb (no. FPLE 201407028) was deposited in 
the Department of Pharmacy, Suizhou Central 
Hospital, China for future reference. Dried Ficus 
pumila Linn. was steeped in water and extracted 
at 60 oC three times for 1 h each. The final 
extract was dried in an oven and freeze-dried. An 
aqueous extract of Ficus pumila Linn. was then 
obtained. One gram powder was equivalent to 
1.8 g crude sample. The yield was 55.6 %. 
 
Metoclopramide was purchased from Xuzhou 
Laien Pharmaceutical Co. Ltd. Bromocriptine 
was obtained from Novartis Pharma Schweiz 





Female virgin Wistar rats weighing 200-220 g 
were provided by the Experimental Animal 
Center of Hubei Province (Certificate no. 
SYXK2007-0005). The animals had free access 
to food and water and were allowed to 
acclimatize for at least 1 week before use. 
Animal experiments were approved by the 
Animal Care and Use Committee of Suizhou 
Central Hospital (approval no. 20120805) and 
were carried out in compliance with Directive 
2010/63/EU on the Handling of Animals used for 
Scientific Purposes [10]. 
 
Preparation of hyperprolactinemic rats and 
FPLE treatment 
 
Hyperprolactinemic rats were generated as 
previously described with slight modifications 
[11]. Metoclopramide dihydrochloride (50 mg/kg) 
was subcutaneously injected into the back of 
rats. Injections were performed twice a day for 5 
consecutive days. 
 
Rats were divided into six groups (n = 10 per 
group): normal control, model (i.e., 
hyperprolactinemic), model plus bromocriptine, 
model plus high dose of FPLE (800 mg/kg), 
model plus moderate dose of FPLE (400 mg/kg), 
and model plus low dose of FPLE (200 mg/kg). 
Each dose of FPLE was dissolved in 2 ml water 
and administered through the mouth to the 
stomach by a syringe. The dosage for rats was 
calculated from the human clinical daily dosage 
of FPLE based on differences in body surface 
area. Control and model rats received 2 ml of 
water only. All rats received intragastric 
administration for 30 days. 
 
Measurements of serum sex hormones 
 
After intragastric administration for 30 days, 
serum estradiol (E2), progesterone (P), PRL, 
follicle-stimulating hormone (FSH), and 
luteinizing hormone (LH) were measured. All 
measurements were performed using ELISA kits 
from Nanjing Jiancheng Inc. (China). 
 
Quantification of pituitary PRL-positive cells  
 
Rat pituitary tissue was embedded in paraffin 
wax. After dewaxing, tissue was incubated with 3 
% H2O2 for 5 min at room temperature. Anti-rat 
PRL antibody (primary antibody, 1:300) was 
applied for 60 min at room temperature, and 
tissue was washed with phosphate-buffered 
saline (PBS) three times. Next, tissue was 
incubated in EnVision reagent including 
secondary and tertiary antibodies for 60 min at 
room temperature and washed with PBS three 
times. Tissue was stained with DAB solution, 
washed with distilled water, and restained. PRL-
positive cells were counted using Microsoft 
software at 200× magnification. 
 
Measurement of pituitary PRL mRNA 
expression 
 
Pituitary tissue was placed into a glass grinder 
with 1 ml Trizol solution. The homogenate was 
placed into a 1.5-ml Eppendorf tube and kept at 
room temperature for 5 min before adding 0.25 
ml chloroform, shaking for 15 s, and resting for 3 
min at room temperature. The solution was 
centrifuged (12000× g) for 15 min at 4 oC. The 
upper aqueous portion was added to an equal 
volume of isopropyl alcohol in a 1.5-ml 
Eppendorf tube and kept for 10 min at room 
temperature before centrifugation (12000× g) for 
10 min at 4 oC.  
 
The supernatant was discarded, 0.9 ml 75 % 
ethanol was added, and the solution was 
centrifuged (10000× g) for 5 min at 4 oC; this step 
was repeated once. The supernatant was 
discarded, and the precipitant was dried at room 
temperature. Next, 30 - 50 μl RNase-free water 
was added to dissolve the RNA sample. The 
RNA sample and primer underwent PCR at 95 
oC for 3 min, and then 5 μl 5× buffer, 5 μl dNTP, 
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1 μl RNA enzyme inhibitor, and 1 μl M-MLV 
reverse transcriptase were successively added in 
an ice-bath. The reverse transcriptase was 
inactivated at 42 oC for 60 min and 95 oC for 2 
min. The PCR amplification system consisted of 
12.5 μl PCR mix, 2 μl rat PRL primers, 2 μl 
internal primer, 2 μl reverse transcription product, 
and RNase-free water.  
 
The solution was centrifuged and mixed, and a 
small amount of sterile liquid paraffin was added 
for 3 min at 94 oC. PCR amplification was carried 
out as follows: 94 oC for 30 s, 56 oC for 30 s, and 
72 oC for 60 s for 23 cycles. The last cycle was 
extended to 8 min at 72 oC. The amplification 
product was placed on 1.5 % agarose gel for 20 
min for 70 V constant voltage electrophoresis, 
and the gray value of the sample was determined 
using a UVP computer image analysis system. 
Using β-actin as an internal control, the relative 





Data are shown as mean ± standard error of the 
mean unless otherwise indicated. Differences 
between groups were analyzed using one-way 
analysis of variance (ANOVA) followed by 
Student’s t-tests. A p-value < 0.05 was 
considered statistically significant. 
RESULTS 
 
Effect of FPLE on serum sex hormones levels 
 
Rats in the model group showed significantly 
higher serum PRL levels (p < 0.01) and lower E2 
(p < 0.01), P (p < 0.01), FSH (p < 0.01), and LH 
(p < 0.05) levels than rats in the control group 
(Table 1). The increased PRL levels in model 
rats were significantly attenuated by treatment 
with bromocriptine (p < 0.01), a moderate dose 
of FPLE (p < 0.01), or a high dose of FPLE (p < 
0.01). Bromocriptine, a moderate dose of FPLE, 
and a high dose of FPLE also significantly 
increased E2 (p < 0.01), P (p < 0.01), FSH (p < 
0.05), and LH (p < 0.05) levels. 
 
Effect of FPLE on pituitary PRL-positive cell 
number 
 
The number of pituitary PRL-positive cells was 
significantly higher in model rats than in control 
rats (p < 0.01; Figure 1). This increased number 
of PRL-positive cells in model rats was 
significantly attenuated by treatment with 
bromocriptine (p < 0.01), a moderate dose of 
FPLE (p < 0.05), and a high dose of FPLE (p < 
0.01). 
 
Table 1: Effect of FPLE on serum sex hormones levels 
 
Group PRL (pg/ml) E2 (pmol/l) P (ng/ml) FSH (IU/l) LH (mIU/ml) 
Control 223.54±6.52 3.06±0.32 1.03±0.05 0.97±0.06 1.71±0.13 
Model 432.14±35.57** 1. 36±0.18** 0.24±0.15** 0.36±0.04** 0.97±0.06* 
BMT 231.69±11.71△△ 2.56±0.26△△ 0.73±0.03△ 0.71±0.02△ 1.62±0.05△ 
FPLE-H 229.15±11.51△△ 2.45±0.15△△ 0.91±0.05△ 0.76±0.02△ 1.71±0.21△ 
FPLE-M 241.62±14.62△△ 2.24±0.38△ 0.81±0.06△ 0.70±0.03△ 1.51±0.04△ 
FPLE-L 304.26±47.22 1.91±0.46 0.38±0.11 0.42±0.07 1.02±0.12 
*p < 0.05，**p < 0.01 vs. control group; △p < 0.05，△△p < 0.01 vs. model group. Values are shown as mean ± 




Figure 1: Pituitary PRL-positive cell numbers. *p <0.05, **p <0.01 vs. model group 
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Figure 2: Pituitary PRL mRNA expression measured by RT-PCR. M: Marker; A: Control group; B: Model group; 
C: Bromocriptine group; D: Low dose of FPLE group; E: Moderate dose of FPLE group; F: High dose of FPLE 
group. 
 
Figure 3: Relative amount of pituitary PRL mRNA expression. *p < 0.05, **p < 0.01 vs. model group 
 
Effect of FPLE on pituitary PRL mRNA 
expression  
 
Model rats showed significantly higher PRL 
mRNA expression than control rats (p < 0.01; 
Figures 2-3). This increased PRL mRNA 
expression in model rats was significantly 
attenuated by treatment with bromocriptine (p < 
0.01), a moderate dose of FPLE (p < 0.05), and 




The hypothalamus-pituitary-gonadal axis plays 
an important role in maintaining normal 
physiological body function and homeostasis of 
the internal environment [12]. However, external 
factors can lead to abnormal sex hormone 
secretion and result in conditions such as 
hyperprolactinemia, hyperplasia of the mammary 
gland, hysteromyoma, and infertility. In 
mammals, PRL regulates mammogenesis, 
promotes milk production, and initiates and 
sustains lactation through autocrine and 
paracrine signaling [13,14]. PRL has many 
functions in breast tissue, including uridine 
conversion, milk protein synthesis, mammary cell 
sodium transport, incorporation into DNA, and 
breast fatty acid synthetase activity [15]. We 
found that hyperprolactinemic rats showed higher 
serum PRL concentrations, as well as lower E2, 
P, FSH, and LH concentrations than control rats. 
However, FPLE attenuated the effects of 
hyperprolactinemia on serum sex hormone 
levels, suggesting that FPLE improves ovary 
function and reduces hyperplasia of the lobules 
and gland alveolus. Furthermore, FPLE 
decreased pituitary PRL-positive cell number and 




The results confirm that Ficus pumila Linn. has 
curative effects in hyperprolactinemia and 
suggest that FPLE treatment can regulate serum 
E2, P, PRL, FSH, and LH levels and decrease 
pituitary PRL-positive cell number and mRNA 
expression in women with hyperprolactinemia. 
Therefore, FPLE should be developed as an anti-
hyperprolactinemia treatment in future work. 
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